EMMA
What one share of Emmaus Life Sciences holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription grade L-glutamine oral powder) is approved by the U.S.
Emmaus Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.23 |
|---|---|
| Profit | −$0.09 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.06 |
| Cash and investments | $0.04 |
| Debt | $0.36 |
| Book value | −$0.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.05 | −$2.52 | $0.05 | −$1.75 | — | $1.06 |
| 2018 | $0.25 | −$1.86 | $0.01 | −$1.75 | — | $0.54 |
| 2018 | $0.45 | −$1.97 | $0.00 | −$0.16 | — | −$0.58 |
| 2019 | $0.54 | −$1.30 | $0.00 | −$0.11 | — | −$0.23 |
| 2021 | $0.42 | −$0.32 | $0.00 | −$0.03 | — | −$0.43 |
| 2022 | $0.37 | −$0.21 | $0.00 | −$0.10 | — | −$0.69 |
| 2023 | $0.56 | −$0.07 | $0.00 | −$0.03 | — | −$0.77 |
| 2024 | $0.26 | −$0.10 | $0.00 | −$0.04 | — | −$0.88 |
| 2025 | $0.19 | −$0.12 | $0.00 | −$0.00 | — | −$0.91 |